CORT — CORCEPT THERAPEUTICS INC catalysts

Name: Bio Catalyst Calendar — source-anchored biotech/pharma catalyst dates
Creator: Bio Catalyst Calendar
License: https://www.usa.gov/government-works

4 verified catalyst event(s) for CORCEPT THERAPEUTICS INC (ticker CORT). Each is linked to its official source. Verified as of 2026-08-06.

Next verified catalyst

2026-09-01 — A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepati · official source ↗

Upcoming

Date	Event	Company	Drug	Official source & verification
2026-09 (month) in 26d ESTIMATED	READOUT A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic St Phase 2 · Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH)	CORT CORCEPT THERAPEUTICS INC	Miricorilant (Cohort A), Miricorilant (C	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-09 (month) in 26d ESTIMATED	READOUT Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Phase 1/2 · Neoplasms	CORT CORCEPT THERAPEUTICS INC	Nenocorilant 200 mg, Nenocorilant 300 mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-10 (month) in 2mo ESTIMATED	READOUT Dazucorilant in Patients With Amyotrophic Lateral Sclerosis Phase 2 · Amyotrophic Lateral Sclerosis	CORT CORCEPT THERAPEUTICS INC	Dazucorilant 300 mg, Dazucorilant 150 mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-12 (month) in 4mo ESTIMATED	READOUT Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patie Phase 2 · Cushing Syndrome	CORT CORCEPT THERAPEUTICS INC	relacorilant	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change